Dehydroepiandrosterone supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.
A growing waistline increases the risk of incident low physical function in the following year among adults with knee osteoarthritis (OA), suggests a recent study. Maintaining waist circumference (WC) may prevent the development of low physical function.
Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis, producing significant reduction in skin fibrosis, according to the results of a phase II trial.
Obesity is tied to adverse outcomes in ankylosing spondylitis, including inflammation, disease activity, physical mobility, radiographic damage, health index, liver function, and cardiovascular risk factors, a study suggests.
The novel Wnt pathway modulator lorecivivint does not appear to be effective for treating pain and inhibiting structural progression in moderate-to-severe knee osteoarthritis (OA), according to the results of a phase IIa trial.
Ritlecitinib, an oral JAK3/TEC inhibitor, appears to be well tolerated and produce significant improvements disease activity in patients with rheumatoid arthritis, according to the results of a phase II study.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.